Completed PHASE2 NCT00746798

Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults

Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults.

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions West Nile Fever

Interventions ChimeriVax-WN02 vaccine Placebo

Updated 6 times since 2017 Last updated: Mar 17, 2015 Started: Oct 31, 2008 Primary completion: Jun 30, 2009 Completion: Dec 31, 2009

Listed as NCT00746798, this PHASE2 trial focuses on West Nile Fever and remains completed. Sponsored by Sanofi Pasteur, a Sanofi Company, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi Pasteur, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Boise, United States , Butte, United States , Colorado Springs, United States , Dallas, United States , Fargo, United States , Fort Worth, United States , Idaho Falls, United States , Lenexa, United States , Missoula, United States and 5 more locations